市場調査レポート

商品コード

乳癌抗体バイオマーカーと臨床試験市場：2028年

Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028

出版日: 2022年04月01日 | 発行: Biomarkers Insights

| ページ情報: 英文 3900 Pages | 納期: 即日から翌営業日

価格

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の乳癌抗体バイオマーカーと臨床試験市場について調査し、モノクローナル抗体、抗体薬物複合体、組み合わせ抗体の概要と臨床試験動向、および市場に参入する企業の競合情勢などを提供しています。

トラスツズマブ（ハーセプチン）
トラスツズマブバイオシミラー（オントルザント）
トラスツズマブバイオシミラー（Ogivri）
トラスツズマブバイオシミラー（ヘルズマ）
トラスツズマブバイオシミラー（トラジメラ）
トラスツズマブバイオシミラー（カンジンティ）
トラスツズマブバイオシミラー（Zercepac/HLX02）
ペルツズマブ（Perjeta）
マルゲツキシマブ（マルゲンザ）
ペムブロリズマブ（Keytruda）
アテゾリズマブ（Tecentriq）
イネテタマブ（Cipterbin）

第3章乳癌抗体薬物複合体-入手可能性、投与量および価格分析

Kadcyla
Enhertu
Trodelvy
Ujvira

第4章組み合わせ抗体-入手可能性、投与量、価格および販売分析

トラスツズマブ、ペルツズマブ、およびヒアルロニダーゼ（フェスゴ）
トラスツズマブとヒアルロニダーゼ注射（ハーセプチンハイレクタ）

第5章乳癌モノクローナル抗体-売上分析

ハーセプチン
カンジンティ
ペルツズマブ
マルゲンザ
キートルーダ
アテゾリズマブ
トラジメラ
フェスゴ

第6章乳癌抗体薬物複合体-売上動向

Kadcyla
Enhertu
Trodelvy

第7章乳癌抗体バイオマーカーと臨床試験動向、企業別、適応別、相別

研究
前臨床
第I相
第I/II相
第II相
第II/III相
第III相
事前登録
登録済み

第8章上市済の乳癌抗体バイオマーカー動向

第9章競合情勢

Amgen
Akesobio
Beigene
Gilead Sciences
Macrogenics
Merck
Pfizer
Roche
Samsung Bio
Zydus Cadila

図表

List of Figures

Figure 1-1: Global - Breast Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 1-2: Global - Breast Cancer Antibodies Market Size (US$ Billion), 2020 & 2021
Figure 1-3: Global - Breast Cancer Antibodies Market by Region (US$ Billion), 2021
Figure 1-4: Global - Breast Cancer Antibodies Market by Region (%), 2021
Figure 1-5: Global - Breast Cancer Antibodies Market by Product (US$ Billion), 2021
Figure 1-6: Global - Breast Cancer Antibodies Market by Product (%), 2021
Figure 1-7: Global - Breast Cancer Antibodies Market Size (US$ Billion), 2022 - 2028
Figure 1-8: US - Breast Cancer Antibodies Market Size (US$ Billion), 2022 - 2028
Figure 2-1: Herceptin - FDA Approval Year by Cancer Type
Figure 2-2: Herceptin -Approval Year by Region
Figure 2-3: US- Price for a Supply of 10 & Price for Single Herceptin 150mg Powder for Injection (US$), February'2022
Figure 2-4: UK- Price for Single Herceptin 150mg Powder for Injection (GBP/US$), February'2022
Figure 2-5: Herceptin - Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg)
Figure 2-6: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), February'2022
Figure 2-7: Herceptin - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
Figure 2-8: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
Figure 2-9: Ontruzant -Approval Year by Region
Figure 2-10: US- Price for 150mg & 420mg Ontruzant Powder for Injection (US$), February'2022
Figure 2-11: UK- Price for Single Ontruzant 150mg Powder for Injection (GBP/US$), February'2022
Figure 2-12: Ontruzant - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 2-13: Ontruzant - Average Cost of Initial Week, Maintenance Week & Annual (US$), February'2022
Figure 2-14: Ontruzant - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
Figure 2-15: Ontruzant - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
Figure 2-16: Ogivri -Approval Year by Region
Figure 2-17: Ogivri - Price for 150mg & 420mg Powder for Injection (US$), February'2022
Figure 2-18: Ogivri - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 2-19: Ogivri - Average Cost of Initial Week, Maintenance Week & Annual (US$), February'2022
Figure 2-20: Ogivri - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
Figure 2-21: Ogivri - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
Figure 2-22: Herzuma -Approval Year by Region
Figure 2-23: US- Price for 150mg & 420mg Herzuma Powder for Injection (US$), February'2022
Figure 2-24: UK- Price for 150mg & 420mg Herzuma Powder for Injection (GBP/US$), February'2022
Figure 2-25: Herzuma - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 2-26: Herzuma - Average Cost of Initial Week, Maintenance Week & Annual (US$), February'2022
Figure 2-27: Herzuma - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
Figure 2-28: Herzuma - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
Figure 2-29: Trazimera -Approval Year by Region
Figure 2-30: US- Price for 150mg & 420mg Trazimera Powder for Injection (US$), February'2022
Figure 2-31: UK- Price for 150mg & 420mg Trazimera Powder for Injection (GBP/US$), February'2022
Figure 2-32: Trazimera - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 2-33: Trazimera - Average Cost of Initial Week, Maintenance Week & Annual treatment (US$), February'2022
Figure 2-34: Trazimera - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
Figure 2-35: Trazimera - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
Figure 2-36: Kanjinti -Approval Year by Region
Figure 2-37: US - Price for 150mg & 420mg Powder for Injection (US$), February'2022
Figure 2-38: UK- Price for 150mg & 420mg Kanjinti Powder for Injection (GBP/US$), February'2022
Figure 2-39: Kanjinti - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 2-40: Kanjinti - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), February'2022
Figure 2-41: Kanjinti - Initial & Maintenance Dose for of Adjuvant Breast Cancer (mg/kg/Week)
Figure 2-42: Kanjinti - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Adjuvant Breast Cancer (US$), February'2022
Figure 2-43: UK- Price for Single Zercepac 150mg Powder for Injection (GBP/US$), February'2022
Figure 2-44: Zercepac - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 2-45: Zercepac - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), February'2022
Figure 2-46: Zercepac - Initial & Maintenance Dose for of Adjuvant Breast Cancer (mg/kg/Week)
Figure 2-47: Zercepac - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Adjuvant Breast Cancer (US$), February'2022
Figure 2-48: Perjeta - Approval Year by Region
Figure 2-49: Perjeta - FDA Approval Year by Cancer Type
Figure 2-50: Perjeta - Patent Expiration Year by Region
Figure 2-51: US- Price for a Supply of 14 ml and Price Per ml of Perjeta Intravenous Solution (US$), February'2022
Figure 2-52: UK- Price for a Supply of 14 ml and Price Per ml of Perjeta Intravenous Solution (GBP/US$), February'2022
Figure 2-53: Perjeta - Initial & Maintenance Dose for Breast Cancer Treatment (mg/3 weeks)
Figure 2-54: Perjeta - Minimum & Maximum Treatment Cost for Breast Cancer (US$), February'2022
Figure 2-55: Perjeta - Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), February'2022
Figure 2-56: Margenza - Price for a Supply of 10 ml and Price Per ml of Intravenous Solution (US$), February'2022
Figure 2-57: Margenza - Price for a Supply of 40 ml and Price Per ml of Intravenous Solution (US$), February'2022
Figure 2-58: Margenza - Average Cost of Single Cycle & Annual Treatment (US$), February'2022
Figure 2-59: Keytruda - Approval Year by Region
Figure 2-60: Keytruda - FDA Approval Year by Indication
Figure 2-61: Keytruda - Patent Expiration Year by Region
Figure 2-62: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda Intravenous Injection (US$), February'2022
Figure 2-63: UK - Price for 4ml & Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), February'2022
Figure 2-64: Keytruda - Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), February'2022
Figure 2-65: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US$), February'2022
Figure 2-66: Tecentriq - Approval Year by Region
Figure 2-67: Tecentriq - FDA Approval Year by Indication
Figure 2-68: US- Price for 14ml Supply & Price Per ml of Tecentriq 840mg/14ml Intravenous Injection (US$), February'2022
Figure 2-69: US - Price for 20ml Supply & Price Per ml of Tecentriq 1200mg/20ml Intravenous Injection (US$), February'2022
Figure 2-70: UK- Price for a Supply of 20ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), February'2022
Figure 2-71: UK- Price for a Supply of 14ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), February'2022
Figure 2-72: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), February'2022
Figure 2-73: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), February'2022
Figure 2-74: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1680mg/4 Week Dose (US$), February'2022
Figure 3-1: US - Kadcyla FDA Approval Year by Indication
Figure 3-2: Kadcyla - Approval Year by Region
Figure 3-3: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 3-4: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (US$), January'2022
Figure 3-5: UK - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (GBP/US$), January'2022
Figure 3-6: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 3-7: Kadcyla - Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), January'2022
Figure 3-8: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 3-9: US - Enhertu Orphan Drug Designation Approval & Exclusivity Year
Figure 3-10: Enhertu - Approval Year by Region
Figure 3-11: US - Polivy FDA Approval Year by Indication
Figure 3-12: UK - Cost of Supply of Enhertu 100mg Intravenous Powder (GBP/US$), January'2022
Figure 3-13: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 3-14: Enhertu - Recommended Dose by Cancer Type (mg/Kg)
Figure 3-15: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 3-16: Enhertu - Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)
Figure 3-17: Enhertu - Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)
Figure 3-18: US - Trodelvy FDA Approval by Indication
Figure 3-19: Trodelvy - Approval Year by Region
Figure 3-20: Trodelvy - Patent Expiration by Region
Figure 3-21: Trodelvy - Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 3-22: Trodelvy - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 3-23: India - Price for Single Unit of Ujvira 100mg & 160mg Intravenous Powder for Injection (INR/US$), January'2022
Figure 3-24: India - Price for Single Unit of Branded & Biosimilar Trastuzumab Emtansine 100mg Powder for Injection (INR/US$), January'2022
Figure 3-25: Ujvira - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 3-26: Ujvira - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 4-1: Phesgo - Price for various Supplies of Subcutaneous Solution for Injection (US$), February'2022
Figure 4-2: Phesgo - Duration of Treatment by Type (Cycles)
Figure 4-3: Herceptin Hylecta - Price for 5ml & Price Per ml of Subcutaneous Solution for Injection (US$), February'2022
Figure 4-4: Herceptin Hylecta - Duration of Single Treatment Cycle & Full Treatment (week)
Figure 5-1: Global - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-2: US - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-3: Europe - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-4: Japan - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-5: ROW - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-6: Herceptin - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 5-7: Herceptin - Annual Sales Value by Region (%), 2021
Figure 5-8: Global - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-9: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-10: Global - Kanjinti Annual Sales (US$ Million), 2019 - 2021
Figure 5-11: US - Kanjinti Annual Sales (US$ Million), 2019 - 2021
Figure 5-12: Kanjinti - Annual Sales by Region (US$ Million), 2021
Figure 5-13: Kanjinti - Annual Sales by Region (%), 2021
Figure 5-14: Global - Kanjinti Quarterely Sales (US$ Million), 2021
Figure 5-15: US - Kanjinti Quarterely Sales (US$ Million), 2021
Figure 5-16: Global - Kanjinti Quarterely Sales (US$ Million), 2020
Figure 5-17: US - Kanjinti Quarterely Sales (US$ Million), 2020
Figure 5-18: Global - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-19: US - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-20: Europe - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-21: Japan - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-22: ROW - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-23: Perjeta - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 5-24: Perjeta - Annual Sales Value by Region (%), 2021
Figure 5-25: US - Perjeta Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-26: Global - Margenza Quarterly Sales (US$ Million), 2021
Figure 5-27: Global - Keytruda Annual Sales Value (US$ Billion), 2018 - 2021
Figure 5-28: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 5-29: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 5-30: Global - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 531: US - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-32: Europe - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-33: Japan - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-34: ROW - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-35: Tecentriq - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 5-36: Tecentriq - Annual Sales Value by Region (%), 2021
Figure 5-37: Global - Tecentriq Quarterly Sales Value (US$ Billion), 2021
Figure 5-38: US - Tecentriq Quarterly Sales Value (US$ Billion), 2021
Figure 5-39: US - Tecentriq Quarterly Sales Value (US$ Million), 2020
Figure 5-40: Global - Trazimera Annual Sales (US$ Million), 2020 & 2021
Figure 5-41: US - Trazimera Annual Sales (US$ Million), 2020 & 2021
Figure 5-42: Europe - Trazimera Annual Sales (US$ Million), 2020 & 2021
Figure 5-43: Trazimera - Annual Sales by Region (US$ Million), 2021
Figure 5-44: Trazimera - Annual Sales by Region (US$ Million), 2020
Figure 5-45: Trazimera - Annual Sales by Region (%), 2021
Figure 5-46: Trazimera - Annual Sales by Region (%), 2020
Figure 5-47: Global - Phesgo Annual Sales Value (US$/CHF Million), 2020 & 2021
Figure 5-48: Phesgo - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 5-49: Phesgo - Annual Sales Value by Region (%), 2021
Figure 5-50: Global - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-51: US - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-52: Europe - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 6-1: Global - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 6-2: US - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 6-3: Europe - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 6-4: Japan - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 6-5: ROW - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 6-6: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 6-7: Kadcyla - Annual Sales Value by Region (%), 2021
Figure 6-8: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 6-9: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 6-10: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 6-11: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 6-12: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 6-13: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 6-14: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 6-15: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 6-16: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 6-17: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 6-18: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 6-19: Kadcyla - Annual Sales Value by Region (%). 2020
Figure 6-20: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 6-21: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 6-22: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 6-23: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 6-24: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 6-25: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2019
Figure 6-26: Global - Enhertu Annual Sales (US$ Million), 2020 & 2021
Figure 6-27: Global - Enhertu Quarterly Sales (US$ Million), 2021
Figure 6-28: Global - Enhertu Quarterly Sales (US$ Million), 2020
Figure 6-29: Global - Trodelvy Annual Sales (US$ Million), 2020 & 2021
Figure 6-30: Global - Trodelvy Quarterly Sales (US$ Million), 2021
Figure 6-31: Trodelvy - Annual Sales by Region (US$ Million), 2021
Figure 6-32: Trodelvy - Annual Sales by Region (%), 2021

“Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report” Highlights:

Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion

Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials

Breast Cancer Biomarkers Sourced During Clinical Trials

Breast Cancer Biomarkers Insight By Antibodies Classification

Insight On Biomarkers Sourced From Trials By Drugs & Indication

Biomarker Name & Function Insight By Antibody

Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

The introduction of biomarker has shown to have critical role in the diagnosis and management of cancer. In advancement towards precision medicine, the field of cancer biomarker discovery has rapidly expanded over the last few decades. This has been developed by advances in technologies and approaches including next generation sequencing, mass spectrometry, circulating tumor cells, and cell-free DNA. The discovery and use of specific prognostic and predictive biomarkers have enabled the application of targeted precision therapies to specific molecular subgroups of patients likely to gain benefit. Within breast cancer, recent biomarker discovery efforts have led to the identification and development of several prognostic and predictive biomarkers including multigene signatures.

Till date, three most important biomarkers for breast cancer are estrogen receptor (ER), progesterone receptor (PR) and a receptor called HER2. The levels of these markers can influence how a person with breast cancer is treated in the clinic. Despite these advances, there is still an important clinical need for the development and validation of novel biomarkers with greater sensitivity, specificity, and clinical utility. Among all targeted therapies, immunotherapy is gaining considerable interest for the management of breast cancer. So far, the typical biomarkers like PD-L1 expression and the numbers of immune cells in the tumor are used for identifying potential patients for the therapy.

The high adoption rates of immunotherapeutic approaches in breast cancer management has surged the further research and development activities in breast cancer biomarker market. Currently, large number of ongoing clinical trials is validating the role of novel biomarkers for breast cancer immunotherapy approaches. Recently a study demonstrated that a molecule called the Major Histocompatibility Complex Class II protein (MHC-II), has the potential to be a predictor of immunotherapy benefit with two types of breast cancer including early-stage, triple negative breast cancer (TNBC) and high-risk, oestrogen receptor-positive breast cancer (HR+) when expressed on breast cancer cells. The findings of the association with response in early-stage high-risk HR+ patients suggests that MHC-II may be a useful tool in a broader context for breast cancer and this area would benefit from further study.

As per our report findings, the global breast cancer antibodies market will surpass US$ 15 Billion by 2028. The increasing prevalence of breast cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various breast cancer subtypes. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for breast cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high breast cancer biomarkers market revenue in the coming years.

Although the market is poised to grow in the forthcoming years, the market faces several challenges in terms of reimbursement policies supported by the government. This is further attributed to the high cost of breast cancer treatment, especially in developing nations. Nevertheless, government support in spreading awareness about breast cancer, and the availability of treatment options for the same are likely to create lucrative growth opportunities for the market in the forthcoming years.

Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market's future growth.

1. Global Breast Cancer Antibodies Market

1.1. Current Market Scenario
1.2. Future Market Opportunity

2. Breast Cancer Monoclonal Antibodies - Availability, Patent, Price & Dosage Analysis

2.1. Trastuzumab (Herceptin)
2.2. Trastuzumab Biosimilar (Ontruzant)
2.3. Trastuzumab Biosimilar (Ogivri)
2.4. Trastuzumab Biosimilar (Herzuma)
2.5. Trastuzumab Biosimilar (Trazimera)
2.6. Trastuzumab Biosimilar (Kanjinti)
2.7. Trastuzumab Biosimilar (Zercepac/HLX02)
2.8. Pertuzumab (Perjeta)
2.9. Margetuximab (Margenza)
2.10. Pembrolizumab (Keytruda )
2.11. Atezolizumab (Tecentriq)
2.12. Inetetamab (Cipterbin)

3. Breast Cancer Antibody Drug Conjugates - Availability, Dosage & Price Analysis

3.1. Kadcyla
3.2. Enhertu
3.3. Trodelvy
3.4. Ujvira

4. Combinational Antibodies - Availability, Dosage, Price & Sales Analysis

4.1. Trastuzumab, Pertuzumab, & Hyaluronidase (Phesgo)
4.2. Trastuzumab & Hyaluronidase Injection (Herceptin Hylecta)

5. Breast Cancer Monoclonal Antibodies - Sales Analysis

5.1. Herceptin
5.2. Kanjinti
5.3. Perjeta
5.4. Margenza
5.5. Keytruda
5.6. Tecentriq
5.7. Trazimera
5.8. Phesgo

6. Breast Cancer Antibody Drug Conjugate - Sales Insights

6.1. Kadcyla
6.2. Enhertu
6.3. Trodelvy

7. Breast Cancer Antibodies Biomarkers & Clinical Trials Insight By Company, Indication & Phase

7.1. Research
7.2. Preclinical
7.3. Phase-I
7.4. Phase-I/II
7.5. Phase-II
7.6. Phase-II/III
7.7. Phase-III
7.8. Preregistration
7.9. Registered

8. Marketed Breast Cancer Antibodies Biomarkers Insight

9. Competitive Landscape

9.1. Amgen
9.2. Akesobio
9.3. Beigene
9.4. Gilead Sciences
9.5. Macrogenics
9.6. Merck
9.7. Pfizer
9.8. Roche
9.9. Samsung Bio
9.10. Zydus Cadila

乳癌抗体バイオマーカーと臨床試験市場：2028年

Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028

目次

第1章世界の乳癌抗体市場

第2章乳癌のモノクローナル抗体-入手可能性、特許、価格および投与量の分析

第3章乳癌抗体薬物複合体-入手可能性、投与量および価格分析

第4章組み合わせ抗体-入手可能性、投与量、価格および販売分析

第5章乳癌モノクローナル抗体-売上分析

第6章乳癌抗体薬物複合体-売上動向

第7章乳癌抗体バイオマーカーと臨床試験動向、企業別、適応別、相別

第8章上市済の乳癌抗体バイオマーカー動向

第9章競合情勢

List of Figures

Table of Contents

1. Global Breast Cancer Antibodies Market

2. Breast Cancer Monoclonal Antibodies - Availability, Patent, Price & Dosage Analysis

3. Breast Cancer Antibody Drug Conjugates - Availability, Dosage & Price Analysis

4. Combinational Antibodies - Availability, Dosage, Price & Sales Analysis

5. Breast Cancer Monoclonal Antibodies - Sales Analysis

6. Breast Cancer Antibody Drug Conjugate - Sales Insights

7. Breast Cancer Antibodies Biomarkers & Clinical Trials Insight By Company, Indication & Phase

8. Marketed Breast Cancer Antibodies Biomarkers Insight

9. Competitive Landscape

乳癌抗体バイオマーカーと臨床試験市場：2028年

Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028

目次

第1章 世界の乳癌抗体市場

第2章 乳癌のモノクローナル抗体-入手可能性、特許、価格および投与量の分析

第3章 乳癌抗体薬物複合体-入手可能性、投与量および価格分析

第4章 組み合わせ抗体-入手可能性、投与量、価格および販売分析

第5章 乳癌モノクローナル抗体-売上分析

第6章 乳癌抗体薬物複合体-売上動向

第7章 乳癌抗体バイオマーカーと臨床試験動向、企業別、適応別、相別

第8章 上市済の乳癌抗体バイオマーカー動向

第9章 競合情勢

List of Figures

Table of Contents

1. Global Breast Cancer Antibodies Market

2. Breast Cancer Monoclonal Antibodies - Availability, Patent, Price & Dosage Analysis

3. Breast Cancer Antibody Drug Conjugates - Availability, Dosage & Price Analysis

4. Combinational Antibodies - Availability, Dosage, Price & Sales Analysis

5. Breast Cancer Monoclonal Antibodies - Sales Analysis

6. Breast Cancer Antibody Drug Conjugate - Sales Insights

7. Breast Cancer Antibodies Biomarkers & Clinical Trials Insight By Company, Indication & Phase

8. Marketed Breast Cancer Antibodies Biomarkers Insight

9. Competitive Landscape

第1章世界の乳癌抗体市場

第2章乳癌のモノクローナル抗体-入手可能性、特許、価格および投与量の分析

第3章乳癌抗体薬物複合体-入手可能性、投与量および価格分析

第4章組み合わせ抗体-入手可能性、投与量、価格および販売分析

第5章乳癌モノクローナル抗体-売上分析

第6章乳癌抗体薬物複合体-売上動向

第7章乳癌抗体バイオマーカーと臨床試験動向、企業別、適応別、相別

第8章上市済の乳癌抗体バイオマーカー動向

第9章競合情勢